Translate AMICOR contents if you like

Tuesday, April 03, 2012

monoclonal antibody bapineuzumab


Alzheimer's mAb May Diminish Tau Tangles

Treatment with the monoclonal antibody bapineuzumab significantly lowered levels of phosphorylated tau (P-tau) in the cerebrospinal fluid of Alzheimer's patients, researchers found.
In a pooled analysis from two earlier phase II studies, P-tau levels fell significantly for those on bapineuzumab compared with controls (P=0.03), and there was also a trend toward diminished total-tau levels in these patients, Kaj Blennow, MD, PhD, of the University of Gothenburg in Sweden, and colleagues reported online in the Archives of Neurology.

No comments: